Cassava Sciences (Cassava Sciences) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Cassava Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cassava Sciences's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cassava Sciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Cassava Sciences's Cash-to-Debt or its related term are showing as below:

SAVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 256.46 Med: No Debt Max: No Debt
Current: No Debt

During the past 13 years, Cassava Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 256.46. And the median was No Debt.

SAVA's Cash-to-Debt is ranked better than
99.74% of 1539 companies
in the Biotechnology industry
Industry Median: 6.42 vs SAVA: No Debt

Cassava Sciences Cash-to-Debt Historical Data

The historical data trend for Cassava Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cassava Sciences Cash-to-Debt Chart

Cassava Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

256.46

319.13

989.14

1,446.15

No Debt

Cassava Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															1,446.15	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Cassava Sciences's Cash-to-Debt

For the Biotechnology subindustry, Cassava Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cassava Sciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cassava Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Cassava Sciences's Cash-to-Debt falls into.

Cassava Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Cassava Sciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cassava Sciences had no debt ⁽¹⁾.

Cassava Sciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cassava Sciences had no debt ⁽¹⁾.

Cassava Sciences (NAS:SAVA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Cassava Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Cassava Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Cassava Sciences (Cassava Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cassava Sciences Inc (NAS:SAVA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

SAVA:Mexico PX91:Germany PX91:Germany

Address

6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731

Website

https://www.cassavasciences.com

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.

Executives

Sanford Robertson	director	ONE LETTERMAN DRIVE, BUILDING C SUITE 410, SAN FRANCISCO CA 94129
Richard Barry	director	285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Robert Christopher Cook	officer: SVP & General Counsel	6801 N. CAPITAL OF TEXAS HWY, BUILDING 1, SUITE 300, AUSTIN TX 78731
James William Kupiec	officer: Chief Clinical Dev. Officer	7801 N CAPITAL OF TEXAS HIGHWAY, SUITE 260, AUSTIN TX 78731
Eric Schoen	officer: Chief Financial Officer	7801 N. CAPITAL OF TX HWY, SUITE 260, AUSTIN TX 78731
Remi Barbier	director, 10 percent owner, officer: CEO, Chairman of the Board
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
O Donnell Michael J	director
Robert Z Gussin	director
Scannon Patrick J Md Phd	director	C/O XOMA, LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
Saira Ramasastry	director	501 CANAL BLVD., RICHMOND CA 94804
Nadav Friedmann	director, officer: Chief Scientific Officer
Sabretooth Master Fund, L.p.	10 percent owner	405 LEXINGTON AVENUE, 50TH FLOOR, NEW YORK NY 10174